A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Haematologica

Volumn 99, Issue 6, 2014, Pages

  Korde, Neha ^a   Carlsten, Mattias ^b   Lee, Min Jung ^a   Minter, Alex ^a,c   Tan, Esther ^a,c   Kwok, Mary ^a,c   Manasanch, Elisabet ^a   Bhutani, Manisha ^a   Tageja, Nishant ^a   Roschewski, Mark ^a   Zingone, Adriana ^a   Costello, Rene ^a   Mulquin, Marcia ^a   Zuchlinski, Diamond ^a   Maric, Irina ^c   Calvo, Katherine R ^c   Braylan, Raul ^c   Tembhare, Prashant ^a   Yuan, Constance ^a   Stetler Stevenson, Maryalice ^a   Trepel, Jane ^a   Childs, Richard ^b   Landgren, Ola ^a,d   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical response; HLA C binding KIR2D reports; IPH2101; KIR2D blockade; NK cell function; Smoldering multiple myeloma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; IPH2101; KIR2D; M PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IPH 2101; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ABDOMINAL DISCOMFORT; CHILL; CLINICAL EVALUATION; CLINICAL FEATURE; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER CELL; NAUSEA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA; RECEPTORS, KIR; TREATMENT OUTCOME;

EID: 84901712243     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.103085     Document Type: Letter

References (15)

1. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53(9):1666-76.
2. Benson DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387-91.
3. Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005;129(5):631-43.
4. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008; 143(5):641-53.
5. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood. 2013;121(3):423-30.
6. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5.
7. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-92.
8. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785-9.
9. Rosinol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631-6.
10. Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120(22):4324-33.
11. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317-23.
12. Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2013;369(5):438-47.
13. Landgren O, Mailankody S, Kwok M, Manasanch E, Bhutani M, Tageja N, et al. Carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. 14th International Myeloma Workshop; 2013; Kyoto, Japan.
14. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15):3503-11.
15. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-8.